依达拉奉对急性脑梗死患者血清MMP-2、MMP-9的影响被引量：2

下载PDF

导出

摘要目的探讨依达拉奉对脑梗死患者的治疗作用及对血清中基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)的影响。方法选择35例正常体检者作为对照组,选择住院诊治的110例急性脑梗死患者,随机分为两组,常规治疗组40例采用常规治疗,依达拉奉组70例在常规治疗的基础上加用依达拉奉治疗。两组在治疗前、后行NIHSS评分判定疗效,并应用酶联免疫吸附实验(ELISA)检测治疗前、后患者血清中MMP-2和MMP-9的表达。结果依达拉奉组和常规治疗组治疗后的MMP-2和MMP-9表达均下降,依达拉奉组更明显。结论与常规治疗组相比,依达拉奉治疗脑梗死的效果明显,并能调节血清中MMP-2和MMP-9的表达。

作者胡松筠蒋佩军戴方瑜寇雪莲

机构地区舟山市普陀区中医院舟山市人民医院神经内科

出处《心脑血管病防治》 2010年第6期440-442,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT

关键词急性脑梗死依达拉奉基质金属蛋白酶-2 基质金属蛋白酶-9

分类号 R743.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献11

1Kelly PJ,Morrow JD,Ning M,et al.Oxidative stress and matrix metal loproteinase-9 in acute ischemic strok:the Biomarker Evaluation for Antioxidant Therapies in Stroke(BEAT-Stroke)study[J].Stroke,2008,39(1):100-104.
2Gaeche Y,Soeeal PM,Kanemitsu M,et al.Matrix metal loproteinases and diseases of the central nervous system with a special emphasis on ischemic brain[J].Front Biosci,2006,11:1289-1301.
3Rosell A,Ortega-Aznar A,Alvarez-Sabin J,et al.Increased brain expression of matrix metal.loproteinase-9 after ischemic and hemorrhagic human stroke[J].Stroke,2006,37(6):1399-1406.
4Serena J,Blanco M,Castellanos M,et al.The prediction of malignant cerebral infarction by molecular brain barrier disruption markers[J].Stroke,2005,36(9):1921-1926.
5Neumann-Haefelin T,Kastrup A,de Crespigny A,et al.Serial MRI after Iransient focal cerebral ischemia in rats:dynamics of tissue injury,bloodbrain barrier damage,and edema formation[J].Stroke,2000,31(8):1965-1972:discussion 1972-1973.
6Fatar M,Stroick M,Griebe M,et al.Matrix metalloproteinases in cerebrovascular diseases[J].Cerebrovasc Dis,2005,20(3):141-151.
7Horstmann S,Kalb P,Koziol J,et al.Profiles of matrix metal loproteinases,their inhibitors,and laminin in stroke patients:influence of different therapies[J].Stroke,2003,34(9):2165-2170.
8Montaner J,Molina CA,Monasterio J,et al.Matrix metal loproteinase-9 pretreatment level predicts intraeranial hemorrhagic complications after thrombolysis in human stroke[J].Circulation,2003,107(4):598-603.
9Tanaka M.Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent[J].Nippon Yakurigaku Zasshi,2002,119(5):301-308.
10Edaravone acute Infarction Study Group.Effect of a novd free radical scavenger,edaravone(MCI-186),on acute brain infarction.Randomized,placebo-controlled,double-blind study at multicenters[A].Cerebrovasc Dis,2003,15(3):222-229.